AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Fentiazac helps alleviate mild to moderate pain caused by conditions such as osteoarthritis, rheumatoid arthritis, sprains, strains, and other musculoskeletal injuries.
Anti-inflammatory Effects: Fentiazac reduces inflammation by inhibiting the production of prostaglandins, which are substances in the body that contribute to inflammation, pain, and fever.
Fever Reduction: Like other NSAIDs, fentiazac can also help reduce fever by lowering elevated body temperature caused by infections or inflammatory conditions.
Musculoskeletal Disorders: Fentiazac is commonly prescribed for conditions affecting the joints, muscles, and connective tissues, including arthritis, bursitis, tendonitis, and gout.
Postoperative Pain: Fentiazac may be used to manage pain following surgical procedures, such as orthopedic surgeries or other procedures associated with inflammation and pain.
Topical Formulations: Fentiazac is available in topical formulations (e.g., gels, creams) for localized application to the skin over affected areas, providing targeted relief from pain and inflammation.
Side Effects: Like other NSAIDs, fentiazac may cause side effects, including gastrointestinal disturbances (such as stomach pain, nausea, indigestion), headache, dizziness, skin rash, and allergic reactions in some individuals. Long-term use or high doses of NSAIDs may also increase the risk of cardiovascular events, such as heart attack or stroke, and gastrointestinal complications, such as ulcers or gastrointestinal bleeding.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
ADHD | 1.1 | 1.1 | |
Age-Related Macular Degeneration and Glaucoma | 0.3 | -0.3 | |
Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | |
Allergies | 1.5 | 0.3 | 4 |
Allergy to milk products | 0.4 | 0.3 | 0.33 |
Alopecia (Hair Loss) | 0.3 | 0.3 | |
Alzheimer's disease | 1.3 | 0.7 | 0.86 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.1 | 3 |
Ankylosing spondylitis | 1.1 | 0.5 | 1.2 |
Anorexia Nervosa | 0.3 | 0.3 | 0 |
Antiphospholipid syndrome (APS) | 0.4 | 0.1 | 3 |
Asthma | 0.3 | -0.3 | |
Atherosclerosis | 0.2 | 0.2 | |
Atrial fibrillation | 0.9 | 0.9 | 0 |
Autism | 2.5 | 1.6 | 0.56 |
Barrett esophagus cancer | 0.2 | 0.3 | -0.5 |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.7 | 0 | 0 |
Brain Trauma | 0.3 | -0.3 | |
Carcinoma | 1 | 0.6 | 0.67 |
Celiac Disease | 0.7 | 0.6 | 0.17 |
Cerebral Palsy | 0.3 | 0.3 | 0 |
Chronic Fatigue Syndrome | 1.5 | 1.7 | -0.13 |
Chronic Kidney Disease | 0.6 | 0.6 | |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.9 | |
Chronic Urticaria (Hives) | 0.5 | 0.6 | -0.2 |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.4 | 1 |
Colorectal Cancer | 2.4 | 2.4 | |
Constipation | 0.3 | 0.3 | |
Coronary artery disease | 0.1 | 0.1 | |
COVID-19 | 2.7 | 2.4 | 0.13 |
Crohn's Disease | 2.4 | 1.1 | 1.18 |
cystic fibrosis | 0.2 | 0.3 | -0.5 |
deep vein thrombosis | 0.2 | 0.4 | -1 |
Depression | 3.4 | 1.8 | 0.89 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 0.1 | 1.5 | -14 |
Endometriosis | 1 | 0 | 0 |
Eosinophilic Esophagitis | 0.2 | 0.2 | |
Epilepsy | 1.2 | 1.3 | -0.08 |
Fibromyalgia | 1.1 | 1.2 | -0.09 |
Functional constipation / chronic idiopathic constipation | 1.1 | 0.9 | 0.22 |
gallstone disease (gsd) | 0.4 | 0.2 | 1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
Generalized anxiety disorder | 0.4 | 0.3 | 0.33 |
Glioblastoma | 0.3 | -0.3 | |
Graves' disease | 0.5 | 0.5 | |
Halitosis | 0.4 | 0.3 | 0.33 |
Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 0 | 0 |
hyperglycemia | 0.1 | 0.5 | -4 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.9 | 1 | -0.11 |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 1 | -1 | |
Inflammatory Bowel Disease | 2 | 1.3 | 0.54 |
Insomnia | 0.6 | 0.3 | 1 |
Intelligence | 0.7 | 0.3 | 1.33 |
Intracranial aneurysms | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 0.4 | 1.2 | -2 |
Liver Cirrhosis | 1.2 | 0.7 | 0.71 |
Long COVID | 1.2 | 0.8 | 0.5 |
Lung Cancer | 0.1 | 0 | 0 |
ME/CFS with IBS | 0.3 | 0.3 | 0 |
ME/CFS without IBS | 0.5 | 0.6 | -0.2 |
Metabolic Syndrome | 1.7 | 2.1 | -0.24 |
Mood Disorders | 3.4 | 1.8 | 0.89 |
multiple chemical sensitivity [MCS] | 1.1 | 1.1 | |
Multiple Sclerosis | 2.2 | 1.9 | 0.16 |
Multiple system atrophy (MSA) | 0.6 | 0 | 0 |
Neuropathy (all types) | 0.3 | 0.1 | 2 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.3 | 1.33 |
Obesity | 1.1 | 1.6 | -0.45 |
obsessive-compulsive disorder | 3.1 | 0.6 | 4.17 |
Osteoarthritis | 0.7 | 0 | 0 |
Osteoporosis | 0.3 | 0.3 | 0 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 0.8 | 0.9 | -0.13 |
Polycystic ovary syndrome | 0.6 | 0 | 0 |
Premenstrual dysphoric disorder | 0.3 | -0.3 | |
primary biliary cholangitis | 0.7 | -0.7 | |
Psoriasis | 0.8 | 1.1 | -0.38 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 0.8 | 1.13 |
Rosacea | 0 | 0 | |
Schizophrenia | 1.3 | 0 | 0 |
scoliosis | 0.1 | -0.1 | |
Sjögren syndrome | 1 | 1.2 | -0.2 |
Sleep Apnea | 0.2 | 0.3 | -0.5 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
Stress / posttraumatic stress disorder | 0.8 | 0.3 | 1.67 |
Systemic Lupus Erythematosus | 1.6 | 0 | 0 |
Tic Disorder | 0 | 0.3 | 0 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 0.7 | 0.3 | 1.33 |
Type 2 Diabetes | 1.7 | 2.2 | -0.29 |
Ulcerative colitis | 0.8 | 1.5 | -0.88 |
Unhealthy Ageing | 2.6 | 2.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.